Phosphorylation alters FMRP granules and determines their transport or protein synthesis abilities

Shivani C. Kharod[1], Dongwoo Hwang[2], Heejun Choi[4], Kyle J. Yoon[2], Pablo E. Castillo[1,3] Robert H. Singer[1,2] and Young J. Yoon[1,2,*]

[1] Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, NY 10461
[2] Department of Cell Biology, Albert Einstein College of Medicine, NY 10461
[3] Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, NY 10461
[4] Janelia Research Campus, HHMI, Ashburn, VA 20147

Running title: Phospho-state of FMRP changes granule structure and function

* Correspondence:

Young J. Yoon, Ph.D.
Dominick P. Purpura Department of Neuroscience
Albert Einstein College of Medicine
1300 Morris Park Avenue
Bronx, NY 10461
USA
Email: young.yoon@einsteinmed.edu

Figures: 5, Supplementary Figures: 6, Supplementary Movies: 14

Abstract: 138 words
Introduction: 420 words
Results: 2043 words
Discussion: 916 words
Methods: 2073 words

Abstract

Fragile X messenger ribonucleoprotein (FMRP) is an RNA-binding protein implicated in autism that suppresses translation and forms granules. While FMRP function has been well-studied, how phosphorylation regulates granule binding and function remains limited. Here, we found that Fragile X patient-derived I304N mutant FMRP could not stably bind granules, underscoring the essential nature of FMRP granule association for function. Next, phosphorylation on serine 499 (S499) led to differences in puncta size, intensity, contrast, and transport as shown by phospho-deficient (S499A) and phospho-mimic (S499D) mutant FMRP granules. Additionally, S499D exchanged slowly on granules relative to S499A, suggesting that phosphorylated FMRP can attenuate translation. Furthermore, the S499A mutant enhanced translation in presynaptic boutons of the mouse hippocampus. Thus, the phospho-state of FMRP altered the structure of individual granules, leading to transport and translation to achieve spatiotemporal regulation of local protein synthesis.

KEYWORDS: Fragile X messenger ribonucleoprotein (FMRP), granules, phosphorylation, transport, translation, protein synthesis

Introduction

Fragile X messenger ribonucleoprotein (FMRP) is an RNA-binding protein implicated in mRNA transport and protein synthesis[1-3]. Loss of expression or loss-of-function mutations can lead to intellectual disability with links to autism[4]. In *Fmr1* knock-out mice, the absence of FMRP led to elevated protein production and altered synaptic plasticity[5,6]. At the molecular level, studies have shown that FMRP interacts with translating polyribosomes[7,8] and mRNA[9,10] to regulate protein synthesis and travel along dendrites in an activity-dependent manner[11,12]. In addition, recent studies have elucidated different mechanisms of translational repression by FMRP through interactions with the FMRP-interacting factor, CYFIP1[13], stalled ribosomes[10] and microRNA complexes[14]. In mice, FMRP is phosphorylated on serine 499 (S499) which enhances its association with polysomes and stalled ribosomes[15]. Subsequent studies reported that activation of metabotropic glutamate receptors (mGluR) led to brief dephosphorylation of FMRP by protein phosphatase 2A (PP2A)[16] and facilitated the local translation of *Arc* mRNA in dendrites[17]. Also, dephosphorylated FMRP gets ubiquitinated for degradation by the proteasome[18]. More recently, we reported that FMRP phosphorylation plays a critical role in presynaptic structural and functional plasticity[19]. Altogether, these studies point to phosphorylation of S499 as a critical determinant in regulating FMRP function in translation.

One prominent feature of FMRP in neurons is the formation of Fragile X granules[12,20-22]. FMRP is a multivalent protein that can interact with mRNA, ribosomes, and other regulatory proteins for transport and translational control in dendrites[2,23]. FMRP can also bind with itself to mediate self-assembly into relatively large intracellular structures in vitro[24,25]. However, how changes in FMRP granule structure are linked to changes in FMRP function in living cells remains unresolved. For instance, it is unclear whether the Fragile X patient-derived I304N FMRP mutation, which has lost the ability to bind ribosomes, can still form granules. More importantly, how phosphorylation and dephosphorylation of FMRP can modify the structure of FMRP granules is unexplored. By uncovering the features of FMRP granules that are translation-permissive or translation-repressive, we can predict and assign the function of granules based on their structure and motion.

Here, we have investigated the granule-binding ability of GFP-FMRP, S499A, S499D, and I304N to understand their impact on granule structure and function. Our findings suggest that constitutively phosphorylated S499D mutant possesses greater processivity and long-distance travel of FMRP granules by slowing translation. In contrast, S499A granules may favor scanning through the dendrite through intermittent pauses to deliver newly synthesized proteins at

synapses. Thus, S499 phosphorylation is critical to changes in FMRP granule structure and may

function as a phospho-switch to regulate transport and local protein synthesis.

Results

Patient-derived I304N mutant FMRP does not stably bind FMRP granules

A rare missense mutation on FMRP, I304N, was originally discovered in a Fragile X patient who

exhibited severe autistic behavior but expressed normal levels of FMRP mRNA and protein[26].

Sequencing the *Fmr1* locus revealed that the patient had a missense mutation within the KH2

domain of FMRP. Moreover, I304N mutant FMRP failed to co-fractionate with polyribosomes in

an I304N patient-derived cell line[27] and the I304N mouse model[28]. We wanted to see if the loss

of polysome interaction could affect its ability to bind granules. When we expressed the I304N

FMRP (GFP-I304N) in neurons, we observed very few discrete puncta along with diffuse

fluorescence within dendrites (Fig. 1a). Continuous imaging of GFP-I304N in dendrites showed

no discernible granules over time in kymographs (Fig. 1b), indicating that either it was unable to

bind FMRP granules or that the bound population was obscured by the majority unbound

population. To achieve a higher resolution view of I304N FMRP movement, we conducted single

molecule tracking of individual FMRP proteins using HaloTag-I304N FMRP (Fig. 1c,d). HaloTag

uses self-labeling technology where bright, cell-permeable dyes conjugated to a HaloTag ligand

can covalently bind to the HaloTag, thereby rendering single molecules of Halo-FMRP visible by

fluorescence microscopy[29]. We used deuterated JFX dyes[30], which have improved photostability

ideal for long-term single molecule imaging. When we compared the movement of individual Halo-

FMRP and Halo-I304N molecules, the trajectories for Halo-FMRP were either stationary or

followed a linear path (Fig. 1c and Supplemental Movie 1), suggesting that the moving FMRP

proteins were traveling along the cytoskeleton consistent with active transport. In contrast, most

Halo-I304N molecules appeared untethered with a large degree of freedom in their movement

(Fig. 1d and Supplemental Movie 1). On average, I304N FMRP proteins had higher median

displacement and velocity than Halo-FMRP (Fig. 1e,f). By plotting the particle intensity and size

we confirmed that no changes or loss of signal were observed during image acquisition due to

increased speed or photosensitivity (Fig. 1g,h). These results suggested that while I304N FMRP

had not completely lost affinity for molecular interactions, the binding time was so brief that the

unbound state prevailed where most proteins appeared to be freely diffusing. Notably, the lack of

stable granule-binding by the I304N FMRP would indicate that its interaction with ribosomes is

essential for FMRP granules, and loss of FMRP on granules is linked to FXS pathophysiology.

S499 phospho-mutant FMRP form distinct granules

From activity-dependent dephosphorylation[16,17] to hierarchical phosphorylation of neighboring

serine residues[15,31], S499 has been implicated as the major phospho-switch that governs FMRP

function[23,32]. We reasoned that mutations on S499 that block or mimic phosphorylation would
allow us to capture intermediates of FMRP granules. We generated N-terminal GFP fusions to
wildtype and phospho-mutant FMRP[15] driven by the human Synapsin promoter (Fig. 2a). FMRP
reporters were expressed in cultured hippocampal neurons at DIV7 for one week to assemble
with endogenous FMRP granules. As FMRP granules contain more than one FMRP[21], reporter
expression results in exchange with FMRP in granules and becomes fluorescent over time (Fig.
2b,c). To confirm incorporation into FMRP granules, we performed immunofluorescence to GFP-
FMRP and endogenous FMRP in dendrites and observed colocalization (Fig. S1a). Moreover, co-
expression of GFP-FMRP with Halo-FMRP[19] or ribosomal protein L10A fused to HaloTag showed
colocalization between FMRP with different tags and with ribosomes, respectively (Fig. S1b,c),
demonstrating that our FMRP reporters can assemble onto FMRP granules. As neurons are
sensitive to levels of FMRP[33], we limited the expression of our reporters to one week where we
could detect measurable differences in FMRP granules by fluorescence imaging and particle
analyses using TrackMate[34] on FIJI (Fig. 2d,e). Comparison of average dendritic expression of
GFP-FMRP and the phospho-mimic (S499D) mutant showed similar levels, whereas the
phospho-deficient (S499A) mutant expressed less as a result of degradation by the proteasome[18]
(Fig. S1d).

First, we characterized FMRP granules bound by our FMRP reporters to elucidate size, intensity,
and contrast as indicators of granule dimensions, amount of FMRP molecules present in granules,
and how well each reporter can cluster[35], respectively (Fig. 2f-h). The median diameter of GFP-
FMRP granules was around 0.5 μm, consistent with previous reports[21]. The fluorescence intensity
of GFP-FMRP granules exhibited a large distribution, suggesting that cycles of FMRP
phosphorylation and dephosphorylation can facilitate more FMRP molecules to incorporate into
individual granules. Notably, GFP-FMRP granules showed a range of contrast values
encompassing the phospho-mutants, suggesting a mixed population of granules with either
predominantly phosphorylated or dephosphorylated FMRP granules. The S499A mutant formed
granules that were relatively lower in size and intensity, suggesting that these granules were small
but tightly clustered (Fig. S2a). The higher contrast value can be attributed to S499A being
ubiquitinated and degraded leading to reduced overall dendritic levels[18]. Conversely, the S499D
mutant formed larger granules with slightly higher intensity and lower contrast than S499A,
indicating that S499D is bound diffusely on FMRP granules, giving a less compact appearance
(Fig. S2b). Since S499D mutant had been suggested to bind stalled polysomes preferentially[15],
S499D-containing granules could be more disordered than a translating granule.

FMRP phospho-mutant reporters differ in processive movement

As FMRP granules can travel throughout neurons[11,36,37], we next asked whether FMRP mutants

vary in their transport in dendrites. We acquired short continuous images (50 ms per frame for

400 frames) of dendrites expressing FMRP reporters (Fig. 3a) and used TrackMate (LAP tracker)

to analyze and classify moving particles (Fig. S3a-c and Supplemental Movies 2-4). Rather than

determine whether FMRP granules could move, we took a closer look to analyze and compare

the processive motion of granules in dendrites. Processivity of transport, or continuous activity of

molecular motors before detaching, is an important measure of how efficiently intracellular cargo

can travel in neurons to deliver molecules, such as mRNA, for local protein synthesis. In our

analysis, we defined processive motion as a particle that moves continuously along the same

direction for five or more consecutive frames, where each processive particle can be sorted by its

total displacement. We observed two populations of processive GFP-FMRP granules with high

and low displacements (Fig. 3b). The low displacement population was prominent in

dephosphorylated S499A granules, suggesting they tend to travel shorter distances with

intermittent pauses, consistent with scanning along the dendrite. On the other hand,

phosphorylated S499D granules showed a population with higher displacements indicative of

longer travel distances during each processive motion. These results suggest that phosphorylated

FMRP granules favor long-distance transport while dephosphorylated FMRP granules prefer

stop-and-go processive motion in search of a docking site.

FMRP exchange onto FMRP granules requires translation

Given that FMRP phospho-mutants differ in their ability to associate with granules, this suggested

that FMRP granules were not static structures. We conducted fluorescence recovery after

photobleaching (FRAP) on individual FMRP granules to test whether unbound FMRP proteins

could exchange onto FMRP granules. We used low-power focused UV light to selectively

photobleach a single fluorescent FMRP puncta (Fig. 4a), reaching an average photobleaching

efficiency of 85%. As we did not detect rapid recovery within the first minute, we acquired longer

time-lapse images at 30-second intervals for 20 minutes. The FRAP assay was performed at

room temperature (22 $^\circ$C) to minimize movement of the photobleached granule and to reduce the

likelihood of interference from other granules that actively traffic through dendrites at physiological

temperature.

Intriguingly, we observed a gradual and partial fluorescence recovery of GFP-FMRP (Fig. 4b,c

and Supplemental Movie 5). When the results were fit to a nonlinear regression curve, GFP-

FMRP reached half-maximal recovery after 2.5 minutes (τ = 172.5 s) with an average recovery of

20% after 10 minutes (Fig. 3f, black circles). Also, the recovery plateaus after 10 minutes, which

suggested a steady-state exchange between inside and outside of the granule. In contrast,

G3BP1-GFP, a well-characterized granule protein[38,39], reached around 60% recovery after one

minute (Fig. S4a-c and Supplemental Movie 6). To test whether FMRP exchange depended on

translation, we performed FRAP in the presence of a translation elongation inhibitor,

cycloheximide (CHX), which would result in completely stalled ribosomes. In the presence of CHX,

GFP-FMRP granules exhibited a markedly reduced recovery (Fig. 4d,e and Supplemental Movie

7), suggesting that FMRP bound to CHX-stalled ribosomes do not exchange (Fig. 4f, red circles).

Comparison of recovery at the final timepoint showed a significant difference in fluorescence (Fig.

4g). Use of another translation elongation inhibitor, anisomycin, resulted in a similar reduction in

recovery (Fig. S4d-g and Supplemental Movie 8). Like GFP-FMRP, recovery of S499A topped

out at 20% (Figs. 4h,i, S5a,b and Supplemental Movies 9,10) with slightly faster kinetics ($\tau = 161.0$

s). However, in the presence of CHX, the initial recovery gradually decreased, suggesting that

S499A has a limited affinity for stalled ribosomes in granules. S499D fluorescence recovery was

the slowest ($\tau = 256.5$ s), eventually reaching 20% recovery after 20 minutes (Figs. 4j,k, S5c,d

and Supplemental Movies 11,12). The slow recovery is consistent with S499D binding to

attenuate translating ribosomes which reduced the recovery rate. Surprisingly, the initial recovery

kinetics of S499D was enhanced by CHX-treatment ($\tau = 30.8$ s). As CHX binds to the E-site of

the translating ribosome, the stable interaction between phosphorylated FMRP and ribosomes

may be occluded, leading to a faster exchange. Taken together, our data show that GFP-FMRP

on granules exchange at a timescale consistent with translation, and this exchange is sensitive

to translation inhibitors. Moreover, dephosphorylated FMRP preferentially bind translating

ribosomes and travel short distances, whereas phosphorylated FMRP exchanges slowly due to

attenuating translation while displacing larger distances (Fig. 4l).

Identifying the C-terminal portion of FMRP as a low-complexity region (LCR) was intriguing as it

hinted that FMRP granules may have functional consequences[40]. As FMRP has multiple RNA-

binding domains, such as KH domains and RGG-box, along with the ability to bind ribosomes

through the KH2 domain, it was suggestive that FMRP may undergo phase separation[41]. We

generated a C-terminal truncation mutant, FMRP[1-444] (ΔC-term), which contained the Agenet and

KH1/2 domains and the nuclear export signal but not the S499 and the RGG box to test whether

it could bind to granules. When expressed in neurons, ΔC-term FMRP was able to bind granules,

albeit less clustered (Fig. S6a) as indicated by the large diameter, reduced intensity and contrast

like G3BP1 (Fig. S6b-e), which has been shown to phase separate[42]. These results support the

conclusion that S499 is necessary but not sufficient for tight granule binding. Fluorescence
recovery of ∆C-term FMRP granules was also similar to G3BP1 with fast recovery kinetics (τ =
15.2 s), and CHX-treatment did not affect recovery (Fig. S6f-h and Supplemental Movies 13,14).
Conversely, when we expressed just the C-terminal portion of FMRP[424-614] (FMRP C-term), we
did not detect granules or localization to any discrete subcellular structure (Fig. S6i). While our
results suggest that the C-terminal region of FMRP may not independently form granules, there
could be FMRP-interactors on disparate regions of FMRP that may facilitate phase separation[43,44].

Phospho-deficient FMRP enhances local translation in mossy fiber boutons

Recently, we have shown that presynaptic boutons can perform increased local protein synthesis
in response to presynaptic activity in an FMRP-dependent manner[19,45]. Presynaptic
compartments such as hippocampal mossy fiber boutons provide an ideal subcellular
compartment to observe discrete, measurable differences in protein synthesis. To determine
whether the phospho-state of FMRP can change the translational output in presynaptic boutons,
we injected lentiviruses encoding Halo-FMRP or Halo-S499A into the dentate gyrus region of the
mouse hippocampus to target dentate granule cells, which give rise to mossy fibers. Following
the expression of these constructs, acute hippocampal slices were fluorescently labeled, and
mossy fiber boutons were imaged (Fig. 5a-c). Consistent with our findings in cultured neurons,
we found that the S499A mutant formed granules that were smaller, less bright, and more
compact when compared to Halo-FMRP (Fig. 5d-f). Next, to determine whether the difference in
granule clustering led to causal changes in protein synthesis, we used puromycin (PMY)
incorporation onto nascent peptides[46] to measure the total output of protein synthesis in the mossy
fiber tract (Fig. 5g,h). Using FMRP fluorescence as a mask, we quantified the average intensity
of the colocalized puromycin label and found that S499A granules correlated with an increase in
protein synthesis when compared to Halo-FMRP (Fig. 5i). Our results demonstrate that regulation
of FMRP granule structure and protein synthesis in mossy fiber boutons correlates with the
phosphorylation state of FMRP.

Discussion

In this study, we set out to better understand FMRP granule structure and function. Using FMRP reporters and high resolution imaging in neurons harboring endogenous FMRP granules helped identify distinguishing features that differ in mutant FMRP. For instance, our observation that the FXS patient-derived I304N mutation could not form discrete granules suggests a possible linkage to FXS. The integrity and maintenance of FMRP on granules could be an important factor in neuronal function and physiology.

To capture FMRP granule intermediates, we focused on the well-characterized phospho-switch S499 of FMRP. The current model of FMRP function is that phosphorylation on S499 results in a translation-repressive state, and dephosphorylation leads to a translation-permissive state, where FMRP likely mimics the phosphorylated state in neurons[15]. Upon mGluR activation, FMRP is transiently dephosphorylated, thereby providing a temporal window of protein synthesis in an activity-dependent manner. Using our FMRP phospho-mutant reporters, we could distinguish differences in FMRP granules that were translation-permissive or -repressive (Figs. 2,3). Regarding granule size and contrast, our observations were consistent with our expectations, where the S499A mutant bound smaller and more discrete granules, while the S499D mutant bound larger and less discrete granules relative to GFP-FMRP, reflecting their differing affinities for granules. However, when we looked at the fluorescence intensity of GFP-FMRP granules, on average, they were much brighter than either mutant. By blocking S499 from phosphorylation and subsequent phosphorylation of neighboring serines[15,31], the phospho-mutant FMRP could not be incorporated into granules in numbers comparable to GFP-FMRP. This observation suggests that phosphorylation and dephosphorylation cycles on S499 can promote phosphorylation of neighboring serines such that more GFP-FMRP can bind or assemble onto granules.

Given the differences in granules, we reasoned that the interaction of our FMRP reporters with granules was not a static process. Our FRAP results for GFP-FMRP showed a partial recovery that was blocked by the translation elongation inhibitor, CHX. The observation that GFP-FMRP could exchange on granules through translating ribosomes was inconsistent with the model that FMRP functions predominantly to stall ribosomes. However, it is conceivable that FMRP may be tuning translation to enhance the fidelity of local protein synthesis. For instance, a previous report showed that FMRP binds to its target mRNA along the coding sequence[10], suggesting that FMRP-binding was not sequence-specific within the open reading frames of target transcripts. The results do not exclude the possibility that FMRP interaction with the coding regions of mRNA could

occur on attenuated or stalled ribosomes. Second, our β-actin translation reporter (which is not

an FMRP target) displayed a half-maximal recovery time of around 75 seconds in dendrites[47],

compared to >150 seconds with our GFP-FMRP reporters (Fig. 4), suggesting that FMRP-binding

may be slowing translation. Third, the observation that FMRP occupancy on mRNA can stabilize

target transcripts through codon optimization[48] will likely require active translation to protect FMRP

targets from mRNA surveillance and decay mechanisms[49]. Taken together, there is a possibility

that FMRP may enhance the fidelity of local protein synthesis through attenuation of translation

rates rather than completely stalling translation.

Unexpectedly, S499D mutant exhibited an ability to exchange with CHX-stalled FMRP granules

(Fig. 4j). This result was surprising as phosphorylated FMRP should preferentially remain bound

to stalled ribosomes. The initial rapid recovery or exchange indicated less stable binding to

granules due to CHX-induced stalling. One explanation could be that FMRP may prefer to stall

translation at a specific elongation step of protein synthesis that "locks-in" FMRP onto granules,

and stalling ribosomes with CHX can lead to changes in ribosome conformation, thereby

destabilizing this interaction. The cryo-EM structure of the fly ribosome bound to dFMRP

suggested that KH1 and KH2 domains interact near the peptidyl site (P site) of the 80S ribosome[50].

Structural evidence that CHX binds to the tRNA exit site (E site) to block ribosome translocation

may force the P site to remain fully occupied and unable to ratchet[51,52]. The growing nascent

peptide bound to tRNA in the P site and CHX bound to the E site may occlude stable interaction

between S499D FMRP and the ribosome.

The recovery levels observed in our FRAP assay was consistently around $20 \pm 10\%$ for FMRP

reporters (Fig. 4). Although we have shown that the recovery was translation-dependent, a large

population of FMRP did not recover, and their binding was translation-independent. The source

of this unrecoverable population could be attributed to FMRP bound to the untranslated regions

(UTRs) of mRNA. While there are differing opinions on whether FMRP can preferentially bind

RNA in the coding sequence or the guanine-rich G-quadruplex structures on the 3′UTR[10,53], our

results may indicate the presence of both interactions. Moreover, if FMRP bound to CYFIP1[13] or

microRNA complexes[14] are present, a significant population of FMRP with longer binding-times

may not recover in 20 minutes.

As FMRP is a negative translation regulator, our results support a clear partition of function for

phosphorylation and dephosphorylation. Although FMRP-induced translation stalling has been

simplified as an all-or-none event, it is likely that FMRP functions somewhere in between working

in conjunction with other factors to regulate protein synthesis, such as mRNA stability through

codon optimality[48], nonsense-mediated decay (NMD)[54] or m6A-mediated decay[55], all of which

may not directly lead to or require completely stalled ribosomes. Moreover, it will be interesting to

directly compare the translation rates of FMRP and non-FMRP target mRNAs to determine

whether FMRP preferentially stalls or slows translation. In sum, our report demonstrates that

FMRP granules are dynamic structures, and elucidating how FMRP asserts control of transport

and local protein synthesis may benefit from high resolution studies.

Methods

Animals

Experimental procedures adhered to NIH and Albert Einstein College of Medicine Institutional Animal Care and Use Committee guidelines. Mice were group-housed in a standard 12 hr light/12 hr dark cycle. Dissociated mouse hippocampal neuron culture and acute transverse slices were prepared from male and female mice (P1 and P21-45, respectively): C57BL/6J (Charles River). Plasmids used in this work are available on Addgene. Detailed protocols and reagent information herein are available upon request.

Plasmids and lentivirus production

Lentiviral expression vectors for GFP fused to FMRP, S499A and S499D were prepared by restriction digest cloning using PCR amplification of EGFP-FMRP sequence from p-EGFP-C1-Flag-mFmr1(wt), p-EGFP-C1-Flag-mFmr1(A) or p-EGFP-C1-Flag-mFmr1(D), respectively. The EGFP-FMRP, S499A and S499D plasmids were a gift from Stephanie Ceman (Addgene plasmids #87929, #87913 and #87914). HaloTag versions of FMRP reporters were generated by replacing GFP with HaloTag. The I304N mutant FMRP was generated using Q5 Site-Directed Mutagenesis Kit (NEB). G3BP1-GFP plasmid was a gift from Jeff Chao (Addgene plasmid #119950). Lentiviral particles were generated by transfecting ENV (pMD2.VSVG), packaging (pMDLg/pRRE), REV (pRSV-Rev) along with the expression vector into HEK293T cells using calcium phosphate. Viral supernatant was concentrated using Lenti-X concentrator (Takara Bio) according to manufacturer's instruction. Virus particles were resuspended in Neurobasal A (Invitrogen) and stored at -80 ^{o}C. High-titer lentivirus were produced in the Einstein Genetic Engineering and Gene Therapy core according to standard protocol. Titer was quantified using fluorescence, RT-PCR and ELISA.

Dissociated mouse hippocampal neuron culture

Post-natal day 1 (P1) mouse hippocampal tissue was isolated from C57BL/6 wildtype newborn pups. Hippocampi were dissociated in 0.25% trypsin, triturated and plated onto poly-D-lysine (Sigma) coated glass-bottomed dishes (MatTek) at 35,000-50,000 cells per dish. Neurons were cultured in Neurobasal A supplemented with B-27 (Invitrogen) and GlutaMAX (Invitrogen).

Slice preparation

Acute transverse slices were prepared as follows: briefly, mice were decapitated, and brains were removed quickly and put into ice cold sucrose cutting solution or NMDG cutting solution. The sucrose cutting solution contained (in mM): 215 sucrose, 20 glucose, 26 $NaHCO_3$, 4 $MgCl_2$, 4

$MgSO_4$, 1.6 NaH_2PO_4, 2.5 KCl, and 1 $CaCl_2$. The NMDG cutting solution contained (in mM): 93

N-Methyl-d-glucamin, 2.5 KCl, 1.25 NaH_2PO_4, 30 $NaHCO_3$, 20 HEPES, 25 D-glucose, 2 Thiourea,

5 Na-Ascorbate, 3 Na-Pyruvate, 0.5 $CaCl_2$, 10 $MgCl_2$. Mice over P35 were cut in NMDG. The

hippocampi were isolated and cut using a VT1200S vibratome (Leica) at a thickness of 300 μm.

The slices were then transferred to 32 °C ACSF for 30 minutes and then kept at room temperature

(RT) for at least 1 hr before recording. For P21 mice: After ice-cold cutting, the slices recovered

at RT (in 50% sucrose, 50% ACSF) for < 30 minutes and then at RT for 1 hr in ACSF. The artificial

cerebrospinal fluid (ACSF) recording solution contained (in mM): 124 NaCl, 26 $NaHCO_3$, 10

glucose, 2.5 KCl, 1 NaH_2PO_4, 2.5 $CaCl_2$, and 1.3 $MgSO_4$. All solutions were bubbled with 95% O_2

and 5% CO_2 for at least 30 minutes. All experiments in acute slices were performed at 25.5 ±

0.1 °C.

Sample preparation and live imaging

Cultured hippocampal neurons were infected with lentivirus at DIV7 and imaged after 3 days at

DIV10 or after one week at DIV14, unless noted otherwise. Prior to imaging, the neurobasal media

was exchanged to Hiberate A low fluorescence (BrainBits) and allowed to equilibrate for 30

minutes at 37 °C prior to imaging at 22 °C. Cycloheximide (CHX, Sigma) 100 μg/ml or anisomycin

(50 μM, Sigma) were introduced into the media after equilibration and allowed to incubate an

additional 30 minutes at 37 °C prior to imaging at 22 °C. For HaloTag labeling, cells were treated

with 10 nM JF549HTL or JF646HTL (Promega) for 15 minutes, followed by 3x washes and

incubation in Hibernate A (low fluorescence) for at least one hour. Cells were washed again in

Hibernate A prior to imaging at 35 °C. For single molecule imaging, 10 nM JFX549 and 10 nM

JFX646 were mixed at 20:1 ratio and added to neuron cultures and labeled for 15 minutes and

washed as above. The deuterated JFX Janelia Fluors were kindly provided by Dr. Luke Lavis at

the Janelia Research Campus.

Stereotaxic injections

WT C57BL/6J mice were stereotactically injected with high titer Halo-FMRP or Halo-S499A

lentivirus into the dentate gyrus region between P21-P24 using established coordinates (-2.2

posterior to Bregma, 2.0 laterally, and 2.0 ventral from dura) using a total volume of 1.5

μL/hemisphere at a flow rate of 0.2 μL/min. After 2-3 weeks of recovery, mice were humanely

killed and acute hippocampal slices were prepared as described above. For labeling Halo-FMRP,

cell-permeable Halo-ligand was bath-applied. Slices were labeled with JF549-HTL (100 nM) in

ACSF in a chamber oxygenated with 95%O_2/5% CO_2 for 1 hour. Slices were fixed with 4% PFA

and mounted using ProLong Diamond (Invitrogen).

Immunofluorescence

For immunofluorescence, neurons were fixed in 4% paraformaldehyde solution (PFA) and permeabilized. After blocking in normal goat serum, cells were treated with primary antibodies: anti-GFP (Aves lab) or anti-FMRP (Abcam; ab17722), followed by secondary antibodies: Goat anti-chicken Alexa Fluor 647 (ThermoFisher) or goat anti-rabbit Cy3 (Sigma) and DAPI. For hippocampal tissue, acute slices were washed twice in 1x PBS then incubated in blocking buffer (4% goat serum in 1x PBS + 2% BSA + 0.1% Tx-100) for 1 hr at RT. Primary antibodies were diluted directly into the antibody buffer (blocking buffer without goat serum) and floating slices were incubated overnight at 4 ⁰C. After 4 washes with 1x PBS, slices were incubated in secondary antibodies (Invitrogen) diluted in blocking buffer overnight at 4 ⁰C. Slices were washed 5x with 1x PBS, then mounted using ProLong Diamond (Invitrogen).

Puromycylation

Acute slices were cut (as described in Slice preparation) 3 weeks after stereotaxic injection and checked for expression using an epifluorescence microscope. Slices were incubated with puromycin (50 µM, Sigma) for 30 minutes. Slices were then fixed for 1 hr in 4% PFA, blocked for 30 minutes, and stained according to the immunohistochemistry protocol above (primary antibodies: anti-ZnT3, rabbit polyclonal, 1:500, Synaptic Systems; anti-puromycin 1:1000, EMD Millipore) and imaged on the Zeiss LSM 880 with Airyscan using a LD LCI Plan-Apochromat 25x/0.8 mm Korr DIC M27 and 1.8x zoom. Images were Airyscan processed prior to analysis. Quantification was performed using FIJI by drawing regions of interest in the ZnT3 channel in which puromycin fluorescence intensity was measured in stratum lucidum. For stratum radiatum control, puromycin signal in regions of interest distal to the stratum lucidum as indicated by the ZnT3 labeling were measured.

Fluorescence microscopy

Acquisition of fluorescence images were performed on a wide field microscope previously described[56]. In brief, the inverted widefield microscope was equipped with 491 nm (Cobolt), 561 nm (Lasertechnik) and 640 nm (Coherent) laser lines along with a UApo 150x 1.45 NA or PlanApo 60x 1.45 NA oil immersion objectives (Olympus). Images were acquired on an EMCCD camera (Andor). Images were 512x512 in size with a pixel size of 106.7 nm (150x) or 266.7 nm (60x). Streaming videos of FMRP granules in dendrites were acquired by continuous imaging at 50 ms intervals for 400 or more frames from a single z-plane. All z-series images (0.2 µm steps) were maximum projected prior to analysis. For photobleaching fluorescent granules, we used the 405 nm UV laser (Omikron) along with a motorized focus lens (Thorlabs) which delivers focused light

to a diffraction limited spot. After acquiring a pre-image, fluorescent granules were exposed to UV

light at 10% power for 5 seconds for photobleaching. Typically, our photobleaching resulted in

greater than 85% average photobleaching efficiency. Time-lapse z-series stacks (21 steps at 0.2

μm per step) were acquired for both 491 nm (GFP) and 561 nm (mCherry) channels every 30

seconds for 41 time-points (20 minutes). The cells were maintained at 22 °C throughout imaging

through a humidified stage top incubator (Tokai Hit). For single molecule imaging of sparsely

labeled Halo-FMRP or Halo-I304N, we first identified neurons labeled with JFX549 and switched

to image JFX646. We acquired streaming images at 50 ms intervals for 1000 images (50 seconds)

using 640 nm laser at high power (50%). We used the first 100 images for particle detection and

tracking analyses. For tissue imaging, images were acquired on a Zeiss LSM 880 with Airyscan

using a Plan-Apochromat 63x/1.4 NA oil DIC M27 and 1.8x zoom. Images were Airyscan

processed prior to analysis. Threshold, laser power, and gain were kept constant for each

experiment. Z-stacks of identical size were taken at similar depths were maximum projected.

Image analysis

Analyses of imaging data were performed using FIJI (ImageJ). For particle detection and tracking

we used the ImageJ plugin TrackMate[34]. We used the Laplacian of Gaussian filter for detection

where the [estimated blob diameter] was set to 5 pixels and [threshold] at 30. These values were

determined empirically by evaluating several randomly selected reference images of GFP-FMRP

and comparing the contrast values of all particles detected: [(intensity inside – intensity outside) /

(intensity inside + intensity outside)][34]. We tested a range of blob diameters from 3 to 6 pixel at

one pixel intervals. Range of threshold values were tested from 15 to 50 at intervals of 5. From

these conditions, we selected blob diameter and threshold values that yielded fewest particles

with negative contrast values (where outside is brighter than inside of the puncta) while limiting

detection of large spurious structures. We also used [median filter] and [sub-pixel localization] for

improved gaussian fit and x-y localization of fluorescent puncta. These conditions were applied

identically to all images to maintain consistency in the analysis. For analysis of Halo-FMRP and

Halo-S499A, we used similar conditions for puncta analysis, except contrast since tissue

generally resulted in variable background from slice to slice. To normalize, we used SNR (signal

to noise) calculation in TrackMate: [(intensity inside – intensity outside) / standard deviation of the

puncta intensity][34]. Statistical comparisons were made using unpaired, two-tailed student's t-test

or Mann-Whitney test in Prism.

For tracking granules, we used the default settings for the [Simple LAP] tracker with [maximum

linking distance] of 5 pixels and [maximum gap-closing distance] of 5 pixels. In most situations

puncta density did not result in overlapping particles. As such, we used the same value as our

blob diameter as the upper-limit for non-diffusive motion. The [maximum gap-closing frame gap]

was set to 2. To select for processively moving particles, we first identified all particle trajectories

using TrackMate and sorted for processivity using our MATLAB script (available on github.com).

In brief, each trajectory of a particle was rotated based on its longest axis of movement, which is

the direction of processive movement. Once rotated, 5 or more consecutive positive or negative

displacements in the long axis was defined as the processive movement. Kymographs of

trafficking puncta were generated using the ImageJ plugin Kymographbuilder.

For single particle tracking, the [estimated blob diameter] was set to 5 pixels and [threshold] at

30. Under high illumination, single JFX dye molecules produce a point spread function that fits a

gaussian profile within the 5-pixel diameter. Next, we used the [Simple LAP] tracker with

[maximum linking distance] of 15 pixels and [maximum gap-closing distance] of 15 pixels, as the

molecules were sparsely populated in the dendrites. The [maximum gap-closing frame gap] was

set to 2. We used less stringent criteria to accommodate particles that were more confined in

Halo-FMRP, relative to Halo-I304N particles that were more freely moving. In addition, we

selected tracks with 5 or more continuously tracked frames to remove spurious detection of fast-

moving dyes and shot noise from the detector.

For FRAP analysis, we selected a 9-pixel circular region of interest (ROI) around the bleach

puncta and measured average intensity within the ROI for all timepoints. The average intensity

values were normalized to pre image (t = -30 s) and the error bars denote standard deviation (SD).

Background fluorescence was measured from a 14x14 area at least 100 pixels away from the site

of photobleaching that did not contain any cellular fluorescence from all timepoints. The average

background fluorescence was subtracted from the average fluorescence from the bleached ROI

at each timepoint. To compare between drug treated and untreated FRAP experiments with

different photobleaching efficiency, the first timepoint after photobleaching was set to baseline

(zero) and all subsequent recovery values were baseline subtracted. The fluorescence recovery

values were fit to a nonlinear regression curve (one-phase association) using Prism to derive time

constants (τ) or time at half-maximal fluorescence of the recovery. The normalized fluorescence

recovery at the final timepoint were analyzed using unpaired, two-tailed student's t-test**.**

Statistical analyses

In all results where statistical information was included, at least three or more independent trials

were performed. Statistical comparisons were made using unpaired student's t-test where p-

values and sample sizes (n) were included in the Figure Legend. Standard deviation (SD) values

were reported for photobleaching results and all others show standard error of the mean (SEM).

 Figure legend

***Figure 1. FXS patient-derived I304N FMRP does not stably bind FMRP granules.* a.**
Representative fluorescence image (pseudo-colored as inverted grayscale) of a dendrite
expressing the I304N mutant FMRP for one week. Scale bar is 5 μm. **b.** Comparison of
kymographs from GFP-FMRP (left) or GFP-I304N (right) expressing dendrites. The discrete
stationary fluorescent puncta present in GFP-FMRP are depicted as continuous lines along the
time-axis while the I304N dendrite does not exhibit any stationary particles. **c.** Sparse labeled
HaloTag-FMRP (Halo-FMRP, pink circles) overlaid with particle trajectories that are color-coded
by total displacement. LUT denotes total displacement during 5 second imaging epoch ranging
from 0 to 3.9 μm. Scale bar is 5 μm. See also Supplemental Movie 1. **d.** Sparse labeled HaloTag-
I304N FMRP (Halo-I304N, pink circles) overlaid with particle trajectories that are color-coded by
total displacement. See also Supplemental Movie 1. LUT denotes total displacement during 5
second imaging epoch ranging from 0 to 4.0 μm. **e.** Scatter plot of total displacement by Halo-
FMRP (black circles; n=359 tracks from 11 cells) and Halo-I304N (red circles; n=299 tracks from
11 cells) particles. The horizontal lines denote population median. Statistical significance was
tested using unpaired, two-tailed Mann-Whitney test. p**** < 0.0001. **f.** Scatter plot of mean
velocity of Halo-FMRP (black circles) and Halo-I304N (red circles) particles. Statistical
significance was tested using unpaired, two-tailed Mann-Whitney test. p**** < 0.0001. **g.** Scatter
plot of mean particle diameter per dendrite of Halo-FMRP (n=11) and Halo-I304N particles (n=11).
The horizontal lines denote population mean. Statistical significance was tested using unpaired,
two-tailed t-test. ns, not significant. **h.** Scatter plot of mean particle intensity per dendrite of Halo-
FMRP and Halo-I304N particles. The horizontal lines denote population mean. Statistical
significance was tested using unpaired, two-tailed t-test. ns, not significant.

***Figure 2. S499 phospho-mutant FMRP form distinct granules.* a.** Schematic of fluorescent
FMRP reporter constructs: human Synapsin promoter drives the expression of GFP-FMRP. Red
lines denote location of I304 and S499. **b.** Cartoon of FMRP reporter in green binding to FMRP
granules. Over time, fluorescent FMRP exchanges with endogenous FMRP which allows
granules to become fluorescent. **c.** A 10x magnification view of cultured neurons expressing GFP-
FMRP labeled with antibodies to GFP shown in green. DAPI is shown in blue. Scale bar is 50 μm.
d. A representative dendrite expressing GFP-FMRP (top panel, inverted grayscale). Same
dendrite shown in 16-color LUT (middle panel). Overlay with TrackMate particle detection (pink
circles, bottom panel). Scale bar is 5 μm. **e.** Surface plot of FMRP puncta shown in the dotted box
in (**d**). Numbers on surface plot correspond to puncta in inset. The LUT indicates the minimum

and maximum fluorescence intensity range. **f.** Violin plots of granule diameter from GFP-FMRP
(green; n=32; 10905 granules), S499A (magenta; n=36; 4923 granules) and S499D (blue; n=14;
3088 granules). Horizontal lines denote population median. Statistical significance was calculated
using unpaired, two-tailed student's t-test. $p^{****} < 0.0001$. **g.** Violin plots of granule fluorescence
intensity from GFP-FMRP (green; n=32), S499A (magenta; n=36) and S499D (blue; n=14).
Horizontal lines denote population median. Statistical significance was calculated using unpaired,
two-tailed student's t-test. $p^{**} < 0.01$; $p^{****} < 0.0001$. **h.** Violin plots of granule contrast from GFP-
FMRP (green; n=32), S499A (magenta; n=36) and S499D (blue; n=14). Horizontal lines denote
population median. Statistical significance was calculated using unpaired, two-tailed student's t-
test. $p^{**} < 0.01$.

Figure 3. FMRP phospho-mutant granules differ in processive movement. a. Fluorescence
images of GFP-FMRP (top), S499A (middle) and S499D (bottom) expressing dendrites overlaid
with tracks detected by TrackMate. LUT indicates velocity at μm/sec and the scale bar is 5 μm.
See also Supplemental Movie 2-4. **b.** Histogram of log10(Displacement) of GFP-FMRP (top,
green), S499A (middle, magenta), and S499D (bottom, blue) granules where displacement is
calculated as the distance from the beginning and end of processive movement in microns.
Histograms were normalized by the total counts in the population. Dotted lines indicate two peaks
from distributions. For GFP-FMRP, $P_{<high\ displacement>} = 0.366$ and $P_{<low\ displacement>} = 0.634$;
Displacement$_{high}$ = 0.58 μm and Displacement$_{low}$ = 0.09 μm. For S499A, $P_{<high\ displacement>} = 0.30$
and $P_{<low\ displacement>} = 0.70$; Displacement$_{high}$ = 0.45 μm and Displacement$_{low}$ = 0.09 μm. For S499D,
$P_{<high\ displacement>} = 0.436$ and $P_{<low\ displacement>} = 0.564$; Displacement$_{high}$ = 0.64 μm and
Displacement$_{low}$ = 0.14 μm.

Figure 4. FMRP granules exchange FMRP proteins in a translation-dependent manner. a.
Schematic of spot photobleaching of individual FMRP granules. **b.** Representative image of GFP-
FMRP granule (green) in dendritic segment (red) selected for the fluorescence recovery assay.
The white arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also
Supplemental Movie 5. **c.** Time-series montage of FMRP granule recovery. Time is noted on the
top-right in seconds. **d.** Representative image of GFP-FMRP granule (green) FRAP in the
presence of cycloheximide (CHX). The white arrowhead indicates the photobleached granule and
the scale bar is 5 μm. See also Supplemental Movie 7. **e.** Time-series montage of FMRP granule
recovery in CHX. **f.** Plot of normalized average fluorescence recovery ± SD (shaded bars) for
granules expressing GFP-FMRP (black circles; n=12) and CHX-treatment (red circles; n=12) over

time. The recovery values were fit to a nonlinear regression curve (gray dashed lines) to calculate time constants (τ). The dotted line indicates the average baseline intensity following photobleaching set to zero. **g.** Normalized recovery at the final timepoint for GFP-FMRP (black circles; n=12) and CHX-treatment (red circles; n=12). Horizontal lines denote population mean. Statistical significance was calculated using unpaired, two-tailed student's t-test. p**** < 0.0001. **h.** Normalized recovery ± SD for S499A granules (black circles; n=10) and CHX-treatment (red circles; n=11). **i.** Normalized recovery at the final timepoint for S499A (black circles; n=10) and CHX-treatment (red circles; n=11). Statistical significance was calculated using unpaired, two-tailed student's t-test. p**** < 0.0001. **j.** Normalized recovery ± SD for S499D granules (black circles; n=8) and CHX-treatment (red circles; n=12). **k.** Normalized recovery at the final timepoint for S499D (black circles; n=8) and CHX-treatment (red circles; n=12). Statistical significance was calculated using unpaired, two-tailed student's t-test. ns, not significant. **l.** Model of how phosphorylation changes FMRP granule dimensions, translation and transport. Dotted circle indicates FMRP granule formed by predominantly phosphorylated (left) or dephosphorylated (right) FMRP. The bidirectional arrow indicates the change in the phospho-state of FMRP. Circled P indicates phosphate groups. Green up-arrow indicates increase and red down-arrow indicates decrease.

Figure 5. Halo-S499A FMRP leads to increased protein synthesis in mossy fiber boutons.
a. Representative tiled fluorescence image of a hippocampal slice expressing Halo-FMRP labeled with JF549 HaloTag ligand after targeted stereotactic injection into the dentate gyrus (DG). Mossy fiber projections (MFs) containing boutons from Halo-FMRP-expressing neurons are shown in the white box. **b-c.** Representative images of mossy fiber boutons expressing Halo-FMRP or Halo-S499A. Scale bar is 10 μm. Insets show higher magnification of boutons **d.** Violin plot of Halo-FMRP (black; n=3650 boutons) and Halo-S499A (red; n=2556 boutons) granule diameters. Horizontal lines denote population median. Statistical significance was calculated using unpaired, two-tailed student's t-test. p**** < 0.0001. **e.** Scatter plot of Halo-FMRP (black; n=3650) and Halo-S499A (red; n=2556) granule intensities. Horizontal lines denote population median. Statistical significance was calculated using unpaired, two-tailed student's t-test. p**** < 0.0001. **f.** Violin plot of Halo-FMRP (black; n=3650) and Halo-S499A (red; n=2556) granule signal-to-noise ratio (SNR). Horizontal lines denote population median. Statistical significance was calculated using unpaired, two-tailed student's t-test. p**** < 0.0001. **g-h.** Representative images of puromycin labeling (PMY, green) and JF549 HaloTag labeling (red) in slices from mice injected with Halo-FMRP (left) or Halo-S499A (right). The FMRP fluorescence was used as a mask to measure puromycin signal.

583 Scale bar is 10 μm. Insets show higher magnification of boutons. **i.** The average intensity of
584 colocalized puromycin label in Halo-FMRP (n=6 slices) and Halo-S499A (n=6 slices) were
585 normalized to Halo-FMRP. Statistical significance was calculated using unpaired, two-tailed
586 student's t-test. p**** < 0.001.

References

1   Bagni, C. & Zukin, R. S. A Synaptic Perspective of Fragile X Syndrome and Autism
Spectrum Disorders. *Neuron* **101**, 1070-1088, doi:10.1016/j.neuron.2019.02.041 (2019).
2   Richter, J. D., Bassell, G. J. & Klann, E. Dysregulation and restoration of translational
homeostasis in fragile X syndrome. *Nat Rev Neurosci* **16**, 595-605, doi:10.1038/nrn4001
(2015).
3   Darnell, J. C. & Klann, E. The translation of translational control by FMRP: therapeutic
targets for FXS. *Nat Neurosci* **16**, 1530-1536, doi:10.1038/nn.3379 (2013).
4   Hagerman, R. J. *et al.* Fragile X syndrome. *Nat Rev Dis Primers* **3**, 17065,
doi:10.1038/nrdp.2017.65 (2017).
5   Qin, M., Kang, J., Burlin, T. V., Jiang, C. & Smith, C. B. Postadolescent changes in
regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. *J Neurosci*
25, 5087-5095, doi:10.1523/JNEUROSCI.0093-05.2005 (2005).
6   Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in
a mouse model of fragile X mental retardation. *Proc Natl Acad Sci U S A* **99**, 7746-7750,
doi:10.1073/pnas.122205699 (2002).
7   Stefani, G., Fraser, C. E., Darnell, J. C. & Darnell, R. B. Fragile X mental retardation
protein is associated with translating polyribosomes in neuronal cells. *J Neurosci* **24**,
7272-7276, doi:10.1523/JNEUROSCI.2306-04.2004 (2004).
8   Khandjian, E. W. *et al.* Biochemical evidence for the association of fragile X mental
retardation protein with brain polyribosomal ribonucleoparticles. *Proc Natl Acad Sci U S*
A **101**, 13357-13362, doi:10.1073/pnas.0405398101 (2004).
9   Brown, V. *et al.* Microarray identification of FMRP-associated brain mRNAs and altered
mRNA translational profiles in fragile X syndrome. *Cell* **107**, 477-487,
doi:10.1016/s0092-8674(01)00568-2 (2001).
10   Darnell, J. C. *et al.* FMRP stalls ribosomal translocation on mRNAs linked to synaptic
function and autism. *Cell* **146**, 247-261, doi:10.1016/j.cell.2011.06.013 (2011).
11   Antar, L. N., Afroz, R., Dictenberg, J. B., Carroll, R. C. & Bassell, G. J. Metabotropic
glutamate receptor activation regulates fragile x mental retardation protein and FMR1
mRNA localization differentially in dendrites and at synapses. *J Neurosci* **24**, 2648-2655,
doi:10.1523/JNEUROSCI.0099-04.2004 (2004).
12   Dictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H. & Bassell, G. J. A direct role
for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine
morphogenesis to fragile X syndrome. *Dev Cell* **14**, 926-939,
doi:10.1016/j.devcel.2008.04.003 (2008).
13   Napoli, I. *et al.* The fragile X syndrome protein represses activity-dependent translation
through CYFIP1, a new 4E-BP. *Cell* **134**, 1042-1054, doi:10.1016/j.cell.2008.07.031
(2008).
14   Muddashetty, R. S. *et al.* Reversible inhibition of PSD-95 mRNA translation by miR-
125a, FMRP phosphorylation, and mGluR signaling. *Mol Cell* **42**, 673-688,
doi:10.1016/j.molcel.2011.05.006 (2011).
15   Ceman, S. *et al.* Phosphorylation influences the translation state of FMRP-associated
polyribosomes. *Hum Mol Genet* **12**, 3295-3305, doi:10.1093/hmg/ddg350 (2003).
16   Narayanan, U. *et al.* FMRP phosphorylation reveals an immediate-early signaling
pathway triggered by group I mGluR and mediated by PP2A. *J Neurosci* **27**, 14349-
14357, doi:10.1523/JNEUROSCI.2969-07.2007 (2007).
17   Niere, F., Wilkerson, J. R. & Huber, K. M. Evidence for a fragile X mental retardation
protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc
translation and long-term depression. *J Neurosci* **32**, 5924-5936,
doi:10.1523/JNEUROSCI.4650-11.2012 (2012).

18   Nalavadi, V. C., Muddashetty, R. S., Gross, C. & Bassell, G. J. Dephosphorylation-
induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early
mGluR-stimulated translation. *J Neurosci* **32**, 2582-2587,
doi:10.1523/JNEUROSCI.5057-11.2012 (2012).
19   Monday, H. R., Kharod, S. C., Yoon, Y. J., Singer, R. H. & Castillo, P. E. Presynaptic
FMRP and local protein synthesis support structural and functional plasticity of
glutamatergic axon terminals. *Neuron* **110**, 2588-2606 e2586,
doi:10.1016/j.neuron.2022.05.024 (2022).
20   Estes, P. S., O'Shea, M., Clasen, S. & Zarnescu, D. C. Fragile X protein controls the
efficacy of mRNA transport in Drosophila neurons. *Mol Cell Neurosci* **39**, 170-179,
doi:10.1016/j.mcn.2008.06.012 (2008).
21   El Fatimy, R. *et al.* Tracking the Fragile X Mental Retardation Protein in a Highly
Ordered Neuronal RiboNucleoParticles Population: A Link between Stalled
Polyribosomes and RNA Granules. *PLoS Genet* **12**, e1006192,
doi:10.1371/journal.pgen.1006192 (2016).
22   Christie, S. B., Akins, M. R., Schwob, J. E. & Fallon, J. R. The FXG: a presynaptic fragile
X granule expressed in a subset of developing brain circuits. *J Neurosci* **29**, 1514-1524,
doi:10.1523/JNEUROSCI.3937-08.2009 (2009).
23   Lai, A., Valdez-Sinon, A. N. & Bassell, G. J. Regulation of RNA granules by FMRP and
implications for neurological diseases. *Traffic* **21**, 454-462, doi:10.1111/tra.12733 (2020).
24   Adinolfi, S. *et al.* The N-terminus of the fragile X mental retardation protein contains a
novel domain involved in dimerization and RNA binding. *Biochemistry* **42**, 10437-10444,
doi:10.1021/bi034909g (2003).
25   Zhang, Y. *et al.* The fragile X mental retardation syndrome protein interacts with novel
homologs FXR1 and FXR2. *EMBO J* **14**, 5358-5366, doi:10.1002/j.1460-
2075.1995.tb00220.x (1995).
26   De Boulle, K. *et al.* A point mutation in the FMR-1 gene associated with fragile X mental
retardation. *Nat Genet* **3**, 31-35, doi:10.1038/ng0193-31 (1993).
27   Feng, Y. *et al.* FMRP associates with polyribosomes as an mRNP, and the I304N
mutation of severe fragile X syndrome abolishes this association. *Mol Cell* **1**, 109-118,
doi:10.1016/s1097-2765(00)80012-x (1997).
28   Zang, J. B. *et al.* A mouse model of the human Fragile X syndrome I304N mutation.
PLoS Genet **5**, e1000758, doi:10.1371/journal.pgen.1000758 (2009).
29   Grimm, J. B. *et al.* A general method to improve fluorophores for live-cell and single-
molecule microscopy. *Nat Methods* **12**, 244-250, 243 p following 250,
doi:10.1038/nmeth.3256 (2015).
30   Grimm, J. B. *et al.* A General Method to Improve Fluorophores Using Deuterated
Auxochromes. *JACS Au* **1**, 690-696, doi:10.1021/jacsau.1c00006 (2021).
31   Bartley, C. M. *et al.* Mammalian FMRP S499 Is Phosphorylated by CK2 and Promotes
Secondary Phosphorylation of FMRP. *eNeuro* **3**, doi:10.1523/ENEURO.0092-16.2016
(2016).
32   Formicola, N., Vijayakumar, J. & Besse, F. Neuronal ribonucleoprotein granules:
Dynamic sensors of localized signals. *Traffic* **20**, 639-649, doi:10.1111/tra.12672 (2019).
33   Arsenault, J. *et al.* FMRP Expression Levels in Mouse Central Nervous System Neurons
Determine Behavioral Phenotype. *Hum Gene Ther* **27**, 982-996,
doi:10.1089/hum.2016.090 (2016).
34   Tinevez, J. Y. *et al.* TrackMate: An open and extensible platform for single-particle
tracking. *Methods* **115**, 80-90, doi:10.1016/j.ymeth.2016.09.016 (2017).
35   Linghu, C. *et al.* Spatial Multiplexing of Fluorescent Reporters for Imaging Signaling
Network Dynamics. *Cell* **183**, 1682-1698 e1624, doi:10.1016/j.cell.2020.10.035 (2020).

36 Antar, L. N., Dictenberg, J. B., Plociniak, M., Afroz, R. & Bassell, G. J. Localization of
FMRP-associated mRNA granules and requirement of microtubules for activity-
dependent trafficking in hippocampal neurons. *Genes Brain Behav* **4**, 350-359,
doi:10.1111/j.1601-183X.2005.00128.x (2005).
37 Antar, L. N., Li, C., Zhang, H., Carroll, R. C. & Bassell, G. J. Local functions for FMRP in
axon growth cone motility and activity-dependent regulation of filopodia and spine
synapses. *Mol Cell Neurosci* **32**, 37-48, doi:10.1016/j.mcn.2006.02.001 (2006).
38 Wilbertz, J. H. *et al.* Single-Molecule Imaging of mRNA Localization and Regulation
during the Integrated Stress Response. *Mol Cell* **73**, 946-958 e947,
doi:10.1016/j.molcel.2018.12.006 (2019).
39 Liao, Y. C. *et al.* RNA Granules Hitchhike on Lysosomes for Long-Distance Transport,
Using Annexin A11 as a Molecular Tether. *Cell* **179**, 147-164 e120,
doi:10.1016/j.cell.2019.08.050 (2019).
40 Tsang, B. *et al.* Phosphoregulated FMRP phase separation models activity-dependent
translation through bidirectional control of mRNA granule formation. *Proc Natl Acad Sci*
U S A **116**, 4218-4227, doi:10.1073/pnas.1814385116 (2019).
41 Riback, J. A. *et al.* Composition-dependent thermodynamics of intracellular phase
separation. *Nature* **581**, 209-214, doi:10.1038/s41586-020-2256-2 (2020).
42 Yang, P. *et al.* G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble
Stress Granules. *Cell* **181**, 325-345 e328, doi:10.1016/j.cell.2020.03.046 (2020).
43 Kim, T. H. *et al.* Phospho-dependent phase separation of FMRP and CAPRIN1
recapitulates regulation of translation and deadenylation. *Science* **365**, 825-829,
doi:10.1126/science.aax4240 (2019).
44 Birsa, N. *et al.* FUS-ALS mutants alter FMRP phase separation equilibrium and impair
protein translation. *Sci Adv* **7**, doi:10.1126/sciadv.abf8660 (2021).
45 Kharod, S. C., Monday, H. R., Yoon, Y. J. & Castillo, P. E. Protocol to study presynaptic
protein synthesis in ex vivo mouse hippocampal slices using HaloTag technology. *STAR*
Protoc **4**, 101986, doi:10.1016/j.xpro.2022.101986 (2023).
46 Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method
to monitor protein synthesis. *Nat Methods* **6**, 275-277, doi:10.1038/nmeth.1314 (2009).
47 Wu, B., Eliscovich, C., Yoon, Y. J. & Singer, R. H. Translation dynamics of single
mRNAs in live cells and neurons. *Science* **352**, 1430-1435, doi:10.1126/science.aaf1084
(2016).
48 Shu, H. *et al.* FMRP links optimal codons to mRNA stability in neurons. *Proc Natl Acad*
Sci U S A **117**, 30400-30411, doi:10.1073/pnas.2009161117 (2020).
49 Doma, M. K. & Parker, R. Endonucleolytic cleavage of eukaryotic mRNAs with stalls in
translation elongation. *Nature* **440**, 561-564, doi:10.1038/nature04530 (2006).
50 Chen, E., Sharma, M. R., Shi, X., Agrawal, R. K. & Joseph, S. Fragile X mental
retardation protein regulates translation by binding directly to the ribosome. *Mol Cell* **54**,
407-417, doi:10.1016/j.molcel.2014.03.023 (2014).
51 Myasnikov, A. G. *et al.* Structure-function insights reveal the human ribosome as a
cancer target for antibiotics. *Nat Commun* **7**, 12856, doi:10.1038/ncomms12856 (2016).
52 Shen, L. *et al.* Structure of the translating Neurospora ribosome arrested by
cycloheximide. *Proc Natl Acad Sci U S A* **118**, doi:10.1073/pnas.2111862118 (2021).
53 Goering, R. *et al.* FMRP promotes RNA localization to neuronal projections through
interactions between its RGG domain and G-quadruplex RNA sequences. *Elife* **9**,
doi:10.7554/eLife.52621 (2020).
54 Kurosaki, T. *et al.* Loss of the fragile X syndrome protein FMRP results in misregulation
of nonsense-mediated mRNA decay. *Nat Cell Biol* **23**, 40-48, doi:10.1038/s41556-020-
00618-1 (2021).

55   Zhang, G. *et al.* Dynamic FMR1 granule phase switch instructed by m6A modification
contributes to maternal RNA decay. *Nat Commun* **13**, 859, doi:10.1038/s41467-022-
28547-7 (2022).
56   Yoon, Y. J. *et al.* Glutamate-induced RNA localization and translation in neurons. *Proc
Natl Acad Sci U S A* **113**, E6877-E6886, doi:10.1073/pnas.1614267113 (2016).
742
743

Acknowledgements

We would like to thank Dr. Hannah Monday for comments and reading of the manuscript. We also thank the Singer lab and Castillo lab members for their comments and discussions. We are grateful to the Lavis lab and HHMI/Janelia Research Campus for the JF dyes. We are also grateful to Stephanie Ceman and Jeff Chao for providing plasmids on Addgene. This research was supported by the National Institutes of Health: R01-MH125772, R01-NS113600, R01-NS115543, R01-MH116673 to P.E.C; R01-NS083085 to R.H.S.; shared instrument grant (S10OD025295) to Kostantin Dobrenis; R21-MH120496 to Y.J.Y.

Author contributions

S.C.K., P.E.C, R.H.S. and Y.J.Y designed the research. S.C.K., D.H. and Y.J.Y. performed the experiments and analyses. H.C. performed particle processivity analysis. K.J.Y. performed single-molecule tracking analysis. S.C.K. and Y.J.Y. wrote the paper and was edited by P.E.C., R.H.S. and Y.J.Y.

Competing interests

The authors declare no competing interests.

Figure 1

Figure 3

Figure 4

Figure 5

1
2
3 **Supplementary Information**
4
5 **Phosphorylation alters FMRP granules and**
6 **determines their transport or protein synthesis abilities**
7
8
9

10 Shivani C. Kharod[1], Dongwoo Hwang[2], Heejun Choi[4], Kyle J. Yoon[2], Pablo E. Castillo[1,3] Robert
11 H. Singer[1,2] and Young J. Yoon[1,2,*]
12
[1] *Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, NY*
10461
[2] *Department of Cell Biology, Albert Einstein College of Medicine, NY 10461*
[3] *Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, NY*
10461
[4] *Janelia Research Campus, HHMI, Ashburn, VA 20147*

19
20
21 Supplementary Figures 1-6
22 Supplementary Movies 1-14

Supplemental figure 1

23
24
Figure S1. FMRP reporters colocalize with endogenous FMRP and Halotagged ribosomal
protein L10A. **a.** Immunofluorescence using antibodies to FMRP (Abcam; ab17722) shown in
green and GFP (Aves lab) in red and merged image on the right. Cultured hippocampal neurons
were infected with lentivirus encoding GFP-FMRP at DIV7, antibody labeled and imaged at DIV14.
High degree of colocalization can be observed. Scale bar is 5 μm. **b.** Live image of dendrites
expressing both GFP-FMRP (green) and Halo-FMRP (red) labeled with JF646, along with the
merged image on the right. Both reporters were expressed in neurons at DIV7 and imaged at
DIV14. Many granules exhibit discrete colocalization of both reporters. Scale bar is 5 μm. **c.** Live

image of dendrites expressing GFP-FMRP (green) and ribosomal protein L10A-Halo (red) labeled
with JF646, along with the merged image on the right. Many granules exhibit colocalization of
reporter proteins. Both reporters were expressed in neurons at DIV7 and imaged at DIV14.Scale
bar is 5 μm. **d.** Average fluorescence intensities from dendrites expression GFP-FMRP (green),
S499A (magenta) and S499D (blue). Statistical significance was calculated using unpaired, two-
tailed student's t-test. $p^{****} < 0.0001$.

Supplemental figure 2

Figure S2. S499 mutant FMRP reporters differ in their binding to FMRP granules. a.
Representative dendrite expressing the GFP-S499A reporter (inverted grayscale). A dendritic
segment is outlined in the dashed box. Scale bar is 10 μm. Top right panel shows the enlarged
dendrite in the dashed box. Scale bar is 5 μm. Middle right panel shows the same dendrite in 16-
color LUT. Bottom panel shows the dendrite overlaid with TrackMate particle detection (pink
circles). Below the panels is a surface plot of S499A puncta shown in the dotted box. Numbers
on surface plot correspond to puncta in inset. The LUT indicates the minimum and maximum
fluorescence intensity range. b. Representative dendrite expressing the GFP-S499D reporter
(inverted grayscale). A dendritic segment is outlined in the dashed box. Scale bar is 10 μm. Top
right panel shows the enlarged dendrite in the dashed box. Scale bar is 5 μm. Middle right panel
shows the same dendrite in 16-color LUT. Bottom panel shows the dendrite overlaid with
TrackMate particle detection (pink circles). Below the panels is a surface plot of S499A puncta
shown in the dotted box. Numbers on surface plot correspond to puncta in inset. The LUT
indicates the minimum and maximum fluorescence intensity range.

Supplemental figure 3

56
57
Figure S3. FMRP reporter containing granules move along dendrites. a. Representative fluorescence image of GFP-FMRP dendrites overlaid with tracks detected by TrackMate. Dendrites were imaged at 50 ms per frame for 400 consecutive frames (20 seconds total; see also Supplemental Movies 2-4). The streaming movies were converted to LUT-inverted kymograph to visualize moving particles along the x-t axis. Horizontal lines indicate non-moving particles and diagonal lines indicate moving particles where the slope indicate the speed (i.e. steeper slope is slower and flatter slope is faster). The tracks were overlaid with color-coded shades to indicate average speed of granule. **b.** Fluorescence image of GFP-S499A dendrite and kymograph. **c.** Fluorescence image of GFP-S499D dendrite and kymograph. LUT indicates average velocity of granules ranging from 0.2 to 10 μm/sec.

Supplemental figure 4

68
69
Figure S4. FMRP granule recovery after photobleaching is different compared to G3BP1
and is sensitive to anisomycin. a. Representative image of G3BP1-GFP granule (green) in
dendritic segment (red) selected for FRAP assay. White arrowhead indicates the photobleached
granule and the scale bar is 5 μm. See also Supplemental Movie 6. **b.** Time-series montage of
G3BP1-GFP granule recovery. Time is noted on the top-right in seconds. **c.** Plot of normalized
average fluorescence recovery ± SD (shaded bars) for G3BP1-GFP granules (brown circles; n=9)
over time. The dotted line indicates the average baseline intensity following photobleaching set
to zero. **d.** Plot of normalized average fluorescence recovery ± SD (shaded bars) for granules
expressing GFP-FMRP under cycloheximide-treatment (CHX, red circles; n=12) or anisomycin-
treatment (Aniso, blue circles; n=5) over time. The recovery values were fit to a nonlinear
regression curve (gray dashed lines) to calculate time constants (τ). The dotted line indicates the
average baseline intensity following photobleaching set to zero. **e.** Plot of normalized recovery at
the final the timepoint for CHX-treatment (red circles; n=12) and Aniso-treatment (blue circles;
n=5). The dotted line indicates the average baseline intensity following photobleaching set to zero.

Horizontal lines denote population median. Statistical significance was calculated using unpaired, two-tailed student's t-test. ns, not significant. **f.** Representative image of GFP-FMRP granule (green) in dendritic segment (red) selected for FRAP assay in the presence of anisomycin (+Aniso). White arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental Movie 8. **g.** Time-series montage of GFP-FMRP granule recovery in the presence of anisomycin. Time is noted on the top-right in seconds.

Supplemental figure 5

Figure S5. FMRP phospho-mutant granule recovery after photobleaching differ between S499A and S499D mutants. **a.** Representative image of GFP-S499A granule (green) in dendritic segment (red) selected for FRAP assay. White arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental Movie 9. On the right is a time-series montage of GFP-S499A granule recovery. Time is noted on the top-right in seconds. **b.** Representative image of GFP-S499A granule (green) in dendritic segment (red) selected for FRAP assay in the presence of cycloheximide (+CHX). White arrowhead indicates the photobleached granule and

the scale bar is 5 μm. See also Supplemental Movie 10. On the right is a time-series montage of
GFP-S499A granule recovery. Time is noted on the top-right in seconds. **c.** Representative image
of GFP-S499D granule (green) in dendritic segment (red) selected for FRAP assay. White
arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental
Movie 11. On the right is a time-series montage of GFP-S499D granule recovery. Time is noted
on the top-right in seconds. **d.** Representative image of GFP-S499D granule (green) in dendritic
segment (red) selected for FRAP assay in the presence of cycloheximide (+CHX). White
arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental
Movie 12. On the right is a time-series montage of GFP-S499D granule recovery. Time is noted
on the top-right in seconds.

a

ΔC-term FMRP

5 μm

b

G3BP1

5 μm

c

Diameter (μm)

ΔC-term   G3BP1

d

Intensity (AU)

ΔC-term   G3BP1

e

Contrast

ΔC-term   G3BP1

f

ΔC-term FMRP
mCherry

5 μm

pre | 0 sec | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240
270 | 300 | 330 | 360 | 390 | 420 | 450 | 480 | 510 | 540
570 | 600 | 630 | 660 | 690 | 720 | 750 | 780 | 810 | 840
870 | 900 | 930 | 960 | 990 | 1020 | 1050 | 1080 | 1110 | 1140

g

ΔC-term FMRP
mCherry

5 μm   +CHX

pre | 0 sec | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 240
270 | 300 | 330 | 360 | 390 | 420 | 450 | 480 | 510 | 540
570 | 600 | 630 | 660 | 690 | 720 | 750 | 780 | 810 | 840
870 | 900 | 930 | 960 | 990 | 1020 | 1050 | 1080 | 1110 | 1140

h

Normalized recovery (%)

Time (sec)

ΔC-term
+CHX

i

5 μm

FMRP C-term

Figure S6. S499 is necessary but not sufficient for granule binding. a. Representative fluorescence image (pseudo-colored as inverted grayscale) of a dendrite expressing the mutant FMRP reporter that does not have the C-terminal region (ΔC-term). Scale bar is 5 μm. **b.** Representative image of G3BP1-GFP granules in dendrites. Scale bar is 5 μm. **c.** Scatter plot of average diameter of fluorescent granules in neurons expressing ΔC-term FMRP (orange; n=8; 2768 granules) or G3BP1 (purple; n=14; 3422 granules). Horizontal lines denote population median. Dashed line indicates median GFP-FMRP granule diameter (0.507 μm). **d.** Scatter plot of average intensity of fluorescent granules in neurons expressing ΔC-term FMRP (orange; n=8) or G3BP1 (purple; n=14). Horizontal lines denote population median. Dashed line indicates median GFP-FMRP granule intensity (765.3 AU). **e.** Scatter plot of average contrast of fluorescent granules in neurons expressing ΔC-term FMRP (orange; n=8) or G3BP1 (purple; n=14). Horizontal lines denote population median. Dashed line indicates median GFP-FMRP granule contrast (0.132). **f.** Representative image of ΔC-term FMRP granule (green) in dendritic segment (red) selected for FRAP assay. White arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental Movie 13. On the right is a time-series montage of ΔC-term FMRP granule recovery. Time is noted on the top-right in seconds. **g.** Representative image of ΔC-term FMRP granule (green) in dendritic segment (red) selected for FRAP assay in the presence of cycloheximide (+CHX). White arrowhead indicates the photobleached granule and the scale bar is 5 μm. See also Supplemental Movie 14. On the right is a time-series montage of ΔC-term FMRP granule recovery. Time is noted on the top-right in seconds. **h.** Plot of normalized average fluorescence recovery ± SD (shaded bars) for ΔC-term FMRP granules (black circles; n=8) and cycloheximide-treatment (CHX, red circles; n=8) over time. The recovery values were fit to a nonlinear regression curve (gray dashed lines) to calculate time constants (τ). The dotted line indicates the average baseline intensity following photobleaching set to zero. **i.** Representative fluorescence image (pseudo-colored as inverted grayscale) of cultured neurons expressing the FMRP C-terminal region (FMRP C-term). Scale bar is 5 μm.

Supplementary Movie 1. Movie of single particle tracking of Halo-FMRP and Halo-I304N. On the top-left is the Halo-FMRP raw images and on the top-right is the Halo-FMRP particles detected by TrackMate (pink circles) overlaid with trajectories color-coded by total displacement. On the bottom-left is the Halo-I304N raw images and on the bottom-right is the Halo-FMRP particles detected by TrackMate (pink circles) overlaid with trajectories color-coded by total displacement. The movie is running at 50 frames per second.

Supplementary Movie 2. Movie of GFP-FMRP granules in dendrites overlaid with tracks. On the left is a dendrite expressing GFP-FMRP and on the right is the same dendrite overlaid with particle tracks detected by TrackMate color-coded by displacement. The movie is running at 50 frames per second.

Supplementary Movie 3. Movie of GFP-S499A granules in dendrites overlaid with tracks. On the left is a dendrite expressing GFP-S499A and on the right is the same dendrite overlaid with particle tracks detected by TrackMate color-coded by displacement. The movie is running at 50 frames per second.

Supplementary Movie 4. Movie of GFP-S499D granules in dendrites overlaid with tracks. On the left is a dendrite expressing GFP-S499D and on the right is the same dendrite overlaid with particle tracks detected by TrackMate color-coded by displacement. The movie is running at 50 frames per second.

Supplementary Movie 5. Movie of GFP-FMRP granule recovery after photobleaching. On the left is a dendrite expressing GFP-FMRP and mCherry where the photobleached granule is circled. Shown on the right is GFP-FMRP only. The movie is running at 15 frames per second.

Supplementary Movie 6. Movie of G3BP1-GFP granule recovery after photobleaching. On the left is a dendrite expressing G3BP1-GFP and mCherry where the photobleached granule is circled. Shown on the right is G3BP1-GFP only. The movie is running at 15 frames per second.

Supplementary Movie 7. Movie of GFP-FMRP granule recovery after photobleaching in cycloheximide. On the left is a dendrite expressing GFP-FMRP and mCherry where the photobleached granule is circled. Shown on the right is GFP-FMRP only. The movie is running at 15 frames per second.

Supplementary Movie 8. Movie of GFP-FMRP granule recovery after photobleaching in anisomycin. On the left is a dendrite expressing GFP-FMRP and mCherry where the photobleached granule is circled. Shown on the right is GFP-FMRP only. The movie is running at 15 frames per second.

Supplementary Movie 9. Movie of GFP-S499A granule recovery after photobleaching. On the left is a dendrite expressing GFP-S499A and mCherry where the photobleached granule is circled. Shown on the right is GFP-S499A only. The movie is running at 15 frames per second.

Supplementary Movie 10. Movie of GFP-S499A granule recovery after photobleaching in cycloheximide. On the left is a dendrite expressing GFP-S499A and mCherry where the photobleached granule is circled. Shown on the right is GFP-S499A only. The movie is running at 15 frames per second.

Supplementary Movie 11. Movie of GFP-S499D granule recovery after photobleaching. On
the left is a dendrite expressing GFP-S499D and mCherry where the photobleached granule is
circled. Shown on the right is GFP-S499D only. The movie is running at 15 frames per second.

Supplementary Movie 12. Movie of GFP-S499D granule recovery after photobleaching in
cycloheximide. On the left is a dendrite expressing GFP-S499D and mCherry where the
photobleached granule is circled. Shown on the right is GFP-S499D only. The movie is running
at 15 frames per second.

Supplementary Movie 13. Movie of ΔC-term FMRP granule recovery after photobleaching.
On the left is a dendrite expressing ΔC-term FMRP and mCherry where the photobleached
granule is circled. Shown on the right is ΔC-term FMRP only. The movie is running at 15 frames
per second.

Supplementary Movie 14. Movie of ΔC-term FMRP granule recovery after photobleaching
in cycloheximide. On the left is a dendrite expressing ΔC-term FMRP and mCherry where the
photobleached granule is circled. Shown on the right is ΔC-term FMRP only. The movie is running
at 15 frames per second.